Spruce Biosciences (SPRB) News
NASDAQ: SPRBHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
SPRB news summary
We found 2 recent headlines mentioning Spruce Biosciences (SPRB): 0 in the past week and 2 in the past 30 days, most often from Nasdaq, Business Wire. SPRB is making an outsized move today, down 6.15% at $38.00, which often coincides with company-specific news. Check the latest headlines below for the likely catalyst. The most recent story, "Spruce Biosciences Reports Third Quarter 2026 Financial Results and Provides Corporate Updates", was published by Nasdaq on Nov 9, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Spruce Biosciences headlines
- Spruce Biosciences Reports Third Quarter 2026 Financial Results and Provides Corporate UpdatesSpruce Biosciences, Inc. announced that its Biologics License Application submission for Tralesinidase Alfa Enzyme Replacement Therapy for the treatment of mucopolysaccharidosis type IIIB remains on…NasdaqSPRB, SUN
- Spruce Biosciences Reports Third Quarter 2026 Financial Results and Provides Corporate UpdatesSOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for…Business Wire